Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06547489 · ClinicalTrials.gov registry record · Phase 2
Zelquistinel or Placebo for the Reduction of Symptoms of Major Depressive Disorder
A Phase 2 study of Major Depressive Disorder, sponsored by Syndeio Biosciences.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 164
- Enrollment target
- 20
- Study locations
NCT06547489 is a Phase 2 study of Major Depressive Disorder that is actively recruiting participants, run by Syndeio Biosciences. The registered enrollment target is 164 participants, below the 376-participant average among 282 other Major Depressive Disorder trials with a reported enrollment target (56% lower). The trial reports 20 study locations across 10 states.
The verdict
NCT06547489, a Phase 2 study of Major Depressive Disorder, is actively recruiting participants, sponsored by Syndeio Biosciences.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 164 participants
- Enrollment target
- 20
- Study locations
Study Summary
The goal of this clinical trial is to learn if zelquistinel works to treat depression in adults. It will also learn about the safety of zelquistinel. The main questions it aims to answer are: Does zelquistinel reduce depression scores in participants compared to participants who take a placebo (a look-alike tablet that contains no zelquistinel)? What medical problems are observed in participants who take zelquistinel? Participants will take one tablet of zelquistinel or placebo every week for 6 weeks. Participants will visit the clinic every week of the 6 week period to have the severity of their depression evaluated.
Conditions Studied
Interventions
- DRUG Zelquistinel
Study Locations (20)
California
- Wr-Pri, Llc - Encino
- Irvine Clinical Research - Irvine
- CalNeuro Research Group - Los Angeles
- Pacific Clinical Research Management Group LLC - Upland
- Sunwise Clinical Research LLC - Walnut Creek
Florida
- Clinical Neuroscience Solutions, Inc. - Jacksonville
- D&H Pompano Research Center, LLC - Margate
- Premier Clinical Research Institute, Inc. - Miami
- Miami Dade Medical Research Institute - Miami
- Clinical Neuroscience Solutions, Inc. - Orlando
Alabama
- University of Alabama at Birmingham - Birmingham
- University of Alabama at Birmingham-Huntsville - Huntsville
Colorado
- MCB Clinical Research Centers, Inc. - Colorado Springs
- Mountain View Clinical Research - Denver
Connecticut
- University of Connecticut School of Medicine Psychiatry Department - Farmington
Georgia
- CenExel iRS (iResearch Savannah) - Savannah
Illinois
- Revive Research Institute - Elgin
Kansas
- KUMC-Wichita - Wichita
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 164 participants |
| Start Date | 2025-02-03 |
| Est. Completion | 2027-12 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06547489
The ClinicalTrials.gov registry entry for NCT06547489 describes a study currently listed as recruiting, categorized as Phase 2. The registered enrollment target is 164 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 376-participant average among 282 other Major Depressive Disorder trials with a reported enrollment target (56% lower). The listed sponsor is Syndeio Biosciences, which has 7 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Major Depressive Disorder appearing as the primary indexed condition, and to 1 intervention - of which Zelquistinel is the first listed.
NCT06547489 reports 20 study locations spanning 10 distinct geographic areas - top geographies include California, Florida, Alabama.
Frequently Asked Questions
What is clinical trial NCT06547489 about?
NCT06547489 is a clinical study titled "Zelquistinel or Placebo for the Reduction of Symptoms of Major Depressive Disorder". The goal of this clinical trial is to learn if zelquistinel works to treat depression in adults. It will also learn about the safety of zelquistinel. The main questions it aims to answer are: Does zelquistinel reduce depression scores in participants compared to participants who take a placebo (a l...
What is the current status of trial NCT06547489?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 164 participants. The study started on 2025-02-03. Estimated completion is 2027-12.
What conditions does trial NCT06547489 study?
This clinical trial studies the following conditions: Major Depressive Disorder.
What interventions are being tested in trial NCT06547489?
The interventions under investigation include: Zelquistinel (DRUG).
Who is sponsoring clinical trial NCT06547489?
This trial is sponsored by Syndeio Biosciences, which has 7 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06547489 being conducted?
This trial has 20 study locations across Alabama, California, Colorado, Connecticut, Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Major Depressive Disorder
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Phase 2 Study of Zelquistinel or Placebo for the Reduction of Symptoms of Major Depressive Disorder
RECRUITING · Phase 2
-
A Study to Assess Change in Disease Activity and Adverse Events of Oral Icalcaprant in Adult Participants With Major Depressive Disorder
RECRUITING · Phase 2
-
Study of ALTO-300 in MDD
RECRUITING · Phase 2
-
Regulation of Affect and Physiology in Depression
RECRUITING · Phase 2
-
Sodium-Glucose Cotransporter-2 Inhibitor (SGLT2) in Major Depressive Disorder (MDD)
RECRUITING · Phase 2
-
A Study of the Efficacy and Safety of SP-624 in the Treatment of Adults With Major Depressive Disorder
RECRUITING · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.